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EXPERT OPINION
Abstract: Acamprosate, a medication that has been used in Europe for years, is the newest
drug to be approved by the US Federal Drug Administration for the treatment of alcohol
dependence. It has been shown to assist in the maintenance of abstinence in recently detoxified
alcohol-dependent individuals. The following review delineates the proposed mechanism of
action and pharmacokinetics of the drug. Findings of clinical trials are outlined and topics
such as cost effectiveness, comparison with other medications used for the treatment of alcohol
dependences as well as combination pharmacotherapy are discussed. In combination with
psychosocial treatment, acamprosate is a promising tool for the maintenance of abstinence in
alcohol-dependent patients after alcohol withdrawal. This review also illustrates the continued
need to search for more effective treatments, as the overall effectiveness of our currently
available pharmacotherapies remains limited in the long-term maintenance of recovery from
alcohol dependence.
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Introduction
The effects of alcoholism on the individual as well as the surrounding community
constitute a major public health issue. The National Institute on Alcohol Abuse and
Alcoholism’s (NIAAA) 2001–2002 National Epidemiologic Survey on Alcohol and
Related Conditions found that the prevalence of alcohol abuse and dependence as
defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV,
APA 1994) in 2001–2002 were 4.65% and 3.81% respectively (Grant et al 2004). It
was estimated that in 2000 there were 63 718 deaths attributable to harmful drinking,
accounting for 4% of all deaths among men and 1.5% among women in the US
(Rivara et al 2004). The price of the health care resulting from alcohol abuse in this
country is estimated at more than US$26 billion per year (US Department of Health
and Human Services 2000). Previous authors have found that alcoholism and resulting
medical comorbidities result in more frequent hospitalizations and longer
hospitalization stays compared with those without substance dependence disorders
(Walker et al 1994). In addition to direct health consequences to the alcoholic, this
disease is associated with escalated risk-taking behaviors that can lead to extensive
indirect harm. For instance, the 2001 National Household Survey on Drug Abuse
found that greater than 1 in 10 Americans aged 12 or older drove under the influence
of alcohol at least once in the 12 months prior to the interview (Substance Abuse and
Mental Health Services Administration 2002). In addition to alcohol-related motor
vehicle crashes, society is affected by crime, fire, destruction, and social welfare
administration. The productivity effects due to alcohol-related illness, premature
deaths, and alcohol-related crimes have been estimated to be greater than $134 million
per year (US Department of Health and Human Services 2000).
The key components in the treatment of an alcohol-dependent individual include
safe withdrawal from alcohol (possibly requiring medicated detoxification),
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maintaining abstinence after withdrawal, and reducing
craving and risk for relapse. Maintaining abstinence in
recently detoxified alcoholic individuals has proven to
be a challenging task. It has been estimated that
approximately 50% of alcoholic patients relapse within
three months after successful detoxification (Whitworth
et al 1996). Psychosocial support has been the cornerstone
in helping individuals maintain abstinence, and
pharmacotherapy is proving to be a valuable addition to
this. Prior to the introduction of acamprosate to the US
market in 2004, only two medications had the US Food
and Drug Administration (FDA) approval for the
treatment of alcohol dependence.
Disulfiram
The first, disulfiram, is an alcohol-deterrent drug. It
interrupts the metabolism of alcohol by inhibiting aldehyde
dehydrogenase, thereby blocking the breakdown of
acetaldehyde to acetate. When alcohol is consumed in
conjuction with disulfiram, levels of acetaldehyde increase
as further metabolism of alcohol is blocked. This increase
in acetaldehyde levels results in nausea, vomiting, and
changes in blood pressure. The patient’s fear of this
disulfiram-alcohol reaction serves as a strong reinforcement
for abstinence (Shuckit and Tapert 2004). Disulfiram has
been used as a treatment for alcohol dependence for over
50 years.
Naltrexone
The second drug, naltrexone, is a pure opioid antagonist.
While its mechanism of action is not fully understood, its
competive antagonism at the opioid receptor is hypothesized
to block the release of dopamine induced by the consumption
of alcohol. By reducing the rewarding effects of alcohol, it
is thought to reduce craving to drink and loss of control
(Sinclair 2001). Naltrexone has been approved in the US
since 1994 for the treatment of alcohol dependence.
Acamprosate
Acamprosate is the newest drug to receive FDA approval
for the treatment of alcohol dependence. It has been used in
Europe for several years and therefore has an abundant body
of literature supporting its efficacy. It has been shown to
assist in the maintenance of abstinence and decrease negative
symptoms associated with the acute post-withdrawal period
in recently detoxified alcohol-dependent individuals (Wilde
and Wagstaff 1997; Forest Pharmaceuticals, Inc. 2005). The
mechanism by which acamprosate helps to maintain
abstinence is not yet fully elucidated. It does not interfere
with or substitute for the reinforcing effects of alcohol
(Littleton and Zieglgansberger 2003). Unlike disulfiram, it
does not produce an aversion to alcohol. It is neither a
sedative nor an anxiolytic agent, and does not have anti-
depressant effects (Anonymous 2005). It is not addictive
and does not provide reinforcing effects of itself (Littleton
1995).
Mechanism of action
While several hypotheses on the mechanisms of action of
acamprosate have been described, the exact mechanism of
action is still not fully understood. The structure of
acamprosate is similar to that of gamma-aminobutyric acid
(GABA), the major inhibitory neurotransmitter in the central
nervous system. It has been found to be active at the N-
methyl-D-aspartate (NMDA) receptor (Knopfel et al 1987).
A likely mechanism of action is the inhibition of neuronal
hyperexcitability mediated by antagonism or modulation of
pre- and post-synaptic activity of excitatory amino acids,
such as glutamate, particularly via modulation of activity at
the NMDA receptor (Scott et al 2005)
Chronic alcohol consumption is believed to negatively
impact the equilibrium between the excitatory glutamatergic
neurotransmitter system and the inhibitory GABAergic
neurotransmitter system. During alcohol intoxication, the
GABAergic system is hyperactive, while it is decreased in
activity during withdrawal (Ueno et al 2001). During
withdrawal, the excitatory neurotransmitter systems,
including glutamate, are hyperactive. By functioning to
increase GABAergic activity and/or inhibiting glutamatergic
activity via modulation of the NMDA receptor, acamprosate
may ameliorate alcohol withdrawal symptomotology
(Dahchour and De Witte 2000; Boeijinga et al 2004).
Pharmacokinetics
The pharmacokinetics of acamprosate have been
investigated in healthy volunteers, in abstinent alcohol-
dependent adults and in individuals with renal or hepatic
insufficiency (Forest Pharmaceuticals, Inc. 2005). The
studies of pharmacokinetics performed by the manufacturer
were then reviewed by Saivin et al (1998) and Durbin et al
(1995).
Acamprosate is poorly absorbed after oral
administration, with an average bioavailability of only 11%.
Time to reach steady state occurs within 5 days of dosing.Neuropsychiatric Disease and Treatment 2006:2(4) 447
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Steady-state peak plasma concentrations (Cmax) after
standard dosing of acamprosate (two 333 mg tablets 3 times
daily) average 350 ng/mL and are reached within 3–8 hours
following dosing (Forest Pharmaceuticals, Inc. 2005). While
co-administration of acamprosate with food decreases its
bioavailability, it is not clinically significant, so that the
medication can be taken with or without food.
The volume of distribution of acamprosate following
intravenous distribution is estimated to be approximately
1 L/kg (72–109L) (Forest Pharmaceuticals, Inc. 2005).
Animal studies indicate that acamprosate crosses the blood-
brain barrier (Durbin et al 1995).
Acamprosate does not undergo metabolism. After oral
dosing of two 333 mg tablets of acamprosate, the average
terminal half-life at steady state ranges between about 20
and 33 hours. The drug is primarily excreted unchanged
through the kidneys (Forest Pharmaceuticals, Inc. 2005).
As the drug has little potential for drug-drug interactions,
acamprosate appears to be safe in individuals taking multiple
medications. In vitro studies indicate that acamprosate does
not induce cytochrome P450 (CYP) 1A2 or 3A4, nor does
it inhibit CYP 1A2, 2C9, 2C19, 2D6, 2E1, or 3A4 (Forest
Pharmaceuticals, Inc. 2005). There are no pharmacokinetic
changes in either drug when acamprosate is given with
alcohol, diazepam or disulfiram.
When acamprosate is given with naltrexone there is a
33% increase in the Cmax for acamprosate; however, this is
not considered clinically relevant and dosage adjustment is
not recommended (Forest Pharmaceuticals, Inc. 2005).
Acamprosate does not appear to have any effects on the
pharmokinetics of naltrexone.
Special patient populations
No significant differences in pharmacokinetics have been
identified based on sex (Saivin et al 1998). As participants
in clinical trials were between the ages of 18 and 65 years,
the pharmacokinetics of acamprosate have not been
evaluated in pediatric or geriatric populations.
As acamprosate is primarily eliminated via the kidneys,
dose adjustment is necessary for individuals with moderate
renal impairment (creatinine clearance of 30–50 m L/min).
Peak plasma concentrations of acamprosate after a standard
dose (666 mg) in individuals with moderate or severe renal
impairment were approximately 2-fold and 4-fold higher,
respectively, compared with healthy subjects (Forest
Pharmaceuticals, Inc 2005). In addition, the half-lives were
1.8-fold and 2.6-fold longer, respectively, compared with
healthy subjects. Individuals with severe renal impairment
(creatinine clearance <30 mL/min) should not be given
acamprosate.
As acamprosate is not metabolized by the liver, the
pharmacokinetics of the drug are not altered in individuals
with mild to moderate hepatic impairment.
Tolerability
In all of the clinical trials to date, acamprosate has been
found to be well tolerated. The drug produces few side-
effects, with diarrhea being the most common complaint.
Occasionally, headaches, dizziness, and pruritis have been
described (Forest Pharmaceuticals, Inc. 2005). Bouza et al
(2004) performed a meta-analysis from 10 studies with
available data on tolerability and found that gastrointestinal
adverse effects were significantly more common in the
acamprosate group compared with placebo, but no statistical
differences were found between the groups in terms of
premature withdrawals from treatment due to adverse events.
Dosage and administration
In the US, as well as Europe, acamprosate is indicated for
maintance of abstinence from alcohol in alcohol-dependent
patients who are abstinent at treatment initiation. Its efficacy
has been demonstrated in the setting of a comprehensive
management program that includes psychosocial support.
The recommended dosage of acamprosate is two 333 mg
tablets (each dose totaling 666 mg) 3 times daily, without
regard to food. It should be initiated as soon as possible
after alcohol withdrawal. Acamprosate should be initiated
during abstinence and should be maintained if the patient
relapses (Forest Pharmaceuticals, Inc. 2005).
Dosage in renal impairment
In individuals with moderate renal impairment (creatinine
clearance of 30–50 mL/min) the starting dose should be
reduced to one 333 mg tablet 3 times daily. Acamprosate
should not be given to individuals with severe renal
impairment (creatinine clearance of < 30 mL/min) (Forest
Pharmaceuticals, Inc. 2005).
Clinical efficacy
Preclinical work with animals has shown that acamprosate
decreases voluntary intake of alcohol and preference for
alcohol over water (Boismare et al 1984; Heyser et al 1988;
Gewiss et al 1991; Spanagel et al 1996; Holter et al 1997;
Czachowski et al 2001; Olive et al 2002). In addition,
Bachteler et al (2005) found that acamprosate significantlyNeuropsychiatric Disease and Treatment 2006:2(4) 448
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and selectively reduced alcohol-seeking behavior in rats
when these animals were re-exposed to environmental cues
predictive of alcohol availability.
The safety and efficacy of acamprosate in humans have
been evaluated in 20 controlled clinical trials conducted in
11 European countries. Three of these trials were identified
as key registration studies by the FDA. These trials are
briefly described in Table 1. In total, the three studies
enrolled 1001 alcohol-dependent outpatients who were
randomized to double-blind treatment with acamprosate or
placebo. In all three studies, psychosocial support was
provided in addition to pharmacotherapy (acamprosate or
placebo).
The results of the studies have generally been
consistent in showing a significant improvement in the
rate of total abstinence and in cumulative abstinence
duration with acamprosate compared with placebo in
association with a variety of different psychosocial
interventions. A beneficial effect on time to first drink
was also frequently observed.
One large study failed to detect a difference between
acamprosate and placebo (Chick et al 2000). This was a
6-month randomized trial undertaken in 20 centers
throughout the UK, including 581 participants. Of note,
medication was not started until an average of 24 days
after the start of detoxification and 32% of patients had
already relapsed by this time. Overall compliance was
poor and there was a high drop out rate. In this study, no
difference was found in abstinent days achieved or in
the percentage of those with complete abstinence at 6
months. Also, no effect on consumption was observed.
The delay in initiating medication, the high rate of relapse
when the medication was started, and the high drop out
rate in comparison to other published trials may very well
have contributed to the lack of a treatment effect in this
study.
Mann et al (2004) performed a large meta-analysis of
randomized, placebo-controlled trials of acamprosate. The
meta-analysis included 17 studies, with a total of 4087
individuals. This meta-analysis revealed that continuous
abstinence rates at 6 months were significantly higher in
the acamprosate-treated subjects. At 12 months, the overall
pooled difference between acamprosate and placebo for
continued abstinence was 13.3%. The effect size in abstinent
rates at 3, 6, and 12 months were 1.33%, 1.50%, and 1.95%
respectively.
Table 1 Key studies leading to FDA approval of acamprosate
Study Design Study subjects Main findings
Pelc et al 1997  90-day, double-blind, placebo-controlled 188 alcohol-dependent males and Acamprosate superior to placebo
trial. Participants randomly assigned to females (18–65 years, weighing (p<0.001) in maintaining abstinence,
1 of 3 groups: acamprosate 1998 mg/day, >60 kg). Subjects were included prolonging time to first drink. Trend
1332 mg/day, or placebo. Study after a 14-day inpatient towards a better effect at higher
medication initiated during 14-day detoxification program, during dosage. Acamprosate appeared to
inpatient detoxification program. which the study medication was be extremely safe.
started.
Sass et al 1996 48-week, double-blind, placebo- 272 newly detoxified alcohol- Those receiving acamprosate
controlled trial. Participants dependent patients from 12 showed higher continuous
randomized to acamprosate were psychiatric outpatient clinics in abstinence rate (p=0.05) and
dosed by weight (weight >60 kg Germany. Subjects had to be  longer mean abstinence duration
received 1998 mg/day; weight abstinent from alcohol for a (p<0.001). Few side-effects with
<60 kg received 1332 mg/day). minimum of 14 days and acamprosate were recorded.
Study medication initiated after maximum of 28 days, and be
14- to 28-day inpatient detoxification free of withdrawal symptoms.
period.
Paille et al 1995 52-week, double-blind, placebo- 538 alcohol-dependent males and Those on high dose acamprosate
controlled trial. Participants randomly females (18–65 years). Subjects were more likely to remain
assigned to 1 of 3 groups: acamprosate had to have undergone abstinent than those on low dose or
1998 mg/day, 1332 mg/day, or placebo. detoxification, be abstinent at placebo (and those on low dose
Study medication initiated after 7- to the time of enrollment, and be acamprosate were more likely to
28-day detoxification period. participating in specialized remain abstinent than placebo).
outpatient treatment for Statistical difference at 6 months
alcoholism.These subjects were (p<0.02) but not at 12 months
predominantly male and tended (p=0.096)
to have a stable lifestyle in terms
of family and occupation.Neuropsychiatric Disease and Treatment 2006:2(4) 449
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Another meta-analysis was conducted to evaluate the
efficacies of disulfiram, the opioid antagonists naltrexone
and nalmefene, acamprosate, various serotonergic agents
(including selective serotonin reuptake inhibitors), and
lithium for the treatment of alcohol dependence (Garbutt et
al 1999). Of 375 articles evaluated, 41 studies and 11 follow
up or subgroup studies were included. Naltrexone reduced
the risk of relapse to heavy drinking and the frequency of
drinking compared to placebo, but did not substantially
enhance abstinence (the avoidance of any alcohol
consumption). Acamprosate reduced drinking frequency, but
its effects on enhancing abstinence or reducing time to first
drink were less clear. Controlled studies of disulfiram were
mixed; it did reduce drinking frequency but there was
minimal evidence that it improved continuous abstinence
rates. Most studies of the serotonergic agents were
confounded by high rates of comorbid mood disorders.
Lithium lacked efficacy in the treatment of alcohol
dependence.
Cost effectiveness
To date, there have been 5 analyses of the cost-effectiveness
of adding acamprosate to pre-existing alcohol rehabilitation
regimens. All 5 studies consistently found that adding
acamprosate to rehabilitation strategies reduces the overall
total costs of treatment (Poldrugo et al 2005). In particular,
Palmer et al (2000) performed a cost-effectiveness analysis
of alcohol abstinence with either standard counseling
therapy or standard therapy plus 48 weeks of adjunctive
acamprosate in detoxified alcoholic patients. Important
complications of alcoholism were considered in the analysis
including relapse, alcohol-related liver disease, acute and
chronic pancreatitis, acute and chronic gastritis,
oropharyngeal carcinoma, esophageal carcinoma, alcoholic
cardiomyopathy, alcohol-related peripheral neuropathy,
alcoholic psychosis, accidental death, and suicide. The
analysis was done on a male cohort with an average age of
41 years, 80% with fatty liver, 15% with cirrhosis, 22%
with chronic pancreatitis, and 1% with alcoholic
cardiomyopathy at baseline. The authors found that life
expectancy was increased in the acamprosate group
compared with those who did not take the drug (15.9
compared with 14.7 years) and average total lifetime costs
per patient were lower in those on acamprosate therapy.
Rychlik et al (2003) conducted an open, prospective,
cohort study in Germany to evaluate the costs of treating
alcohol dependence under real-world conditions over one
year. Of 814 recently detoxified alcohol-dependent patients,
540 were treated with adjuvant acamprosate in addition to
psychosocial rehabilitation support (274 received
psychosocial rehabilitation support but no
pharmacotherapy). Thirty-three percent of acamprosate
patients remained abstinent over the study compared with
only 21.1% in the standard cohort. The mean total costs per
patient treated with acamprosate were significantly less than
those in the standard cohort (€1631.49 and €2068.83
respectively). In this study, direct costs amounted to 76.9%
of the total costs, with a 27% difference between the cohorts.
The cost savings were generated mainly by a reduced rate
of hospitalization.
Comparison of acamprosate with
naltrexone and disulfiram
The three medications currently FDA approved for the
treatment of alcohol dependence are each unique for
mechanism of action, drug interactions, tolerability, and
adverse reactions. Each of the three drugs has its own
advantages and disadvantages. Table 2 outlines some of the
main differences between the drugs. Acamprosate has the
most benign tolerability of the three agents. Naltrexone and
disulfiram offer the ease of 1 tablet, once-daily dosing,
whereas acamprosate therapy consists of 2 tablets dosed 3
times daily (a total of 6 tablets per day). While the multiple
daily dosing schedule and pill burden of acamprosate could
affect compliance, compliance for acamprosate in placebo-
controlled trials was very good.
Kranzler and Van Kirk (2001) performed a meta-analysis
to compare the efficacy of naltrexone and acamprosate. Their
analysis included 9 placebo-controlled naltrexone trials and
11 placebo-controlled acamprosate trials. They found that
both medications significantly, although modestly, affected
drinking outcomes. The strongest effect of both medications
appeared to be on the frequency of the drinking, reflected
by the percentage of drinking days in the naltrexone studies
and by cumulative abstinent days in the acamprosate studies.
Bouza et al (2004) also performed a meta-analysis which
included 13 studies of acamprosate and 19 studies of
naltrexone. This meta-analysis found that acamprosate
significantly improved abstinence rates and days of
cumulative abstinence compared with placebo. Short-term
use of naltrexone reduced the relapse rate significantly.
While short-term use naltrexone was not associated with a
significant modification in abstinence rates, there were
insufficient data to ascertain naltrexone’s efficacy over more
prolonged periods.Neuropsychiatric Disease and Treatment 2006:2(4) 450
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Table 3 briefly describes the trials that have been done
comparing acamprosate directly with naltrexone and
disulfiram. Naltrexone and acamprosate were compared in
a randomized, 12-month, single-blind study involving 157
recently detoxified alcohol-dependent men with moderate
dependence and a stable family environment (Rubio et al
2001). The results of this study favored naltrexone. While
there was no difference in mean time to first drink, time to
first relapse (5 or more drinks in a day) was significantly
greater in the naltrexone group (63 days) compared with
the acamprosate group (42 days) (p=0.02). At the end of
the 12-month study 41% of the naltrexone group compared
with 17% of the acamprosate group had not relapsed
(p=0.009). The cumulative number of days of abstinence
were significantly greater in the naltrexone group, and
severity of craving and percentage of heavy drinking days
was significantly lower in the naltrexone group compared
with the acamprosate group.
Kiefer et al (2003) conducted a 3-month, double-blind,
double dummy, placebo-controlled trial comparing the
efficacy of these two agents with each other, as well as in
combination. One hundred and sixty patients were either
randomized to acamprosate 1998 mg/day as 3 divided doses,
naltrexone 50 mg/day, a combination of the two drugs at
the same doses, or placebo. In this study there was no
significant difference between time to first drink and time
to relapse between acamprosate and naltrexone, and both
were superior to placebo. Time to first drink was
significantly lower in the acamprosate, naltrexone, and
combination groups compared with placebo.
De Sousa and De Sousa (2005) performed an open,
randomized trial in India comparing the efficacy of
acamprosate and disulfiram in preventing alcoholic relapse.
The study included 100 alcohol-dependent males with
highly involved family members who agreed to supervise
the ingestion of the medication and attend appointments with
the patient. In this study, relapse occurred significantly later
in the disulfiram group and a greater proportion of those in
the disulfiram group remained abstinent at the end of the
year long study compared with acamprosate. The results of
this study are difficult to generalize given the extensive
family involvement of the patients. Previous work has found
that without supervised ingestion of disulfiram, compliance
is much lower and therefore the medication is much less
effective.
Combination of naltrexone and
acamprosate
As discussed extensively up to this point, acamprosate has
demonstrated efficacy in maintaining abstinence in
individuals’ status post acute detoxification. Naltrexone has
been shown to reduce relapse into heavy drinking (Kranzler
and Van Kirk 2001; Streeton and Whelan 2001). As neither
acamprosate nor naltrexone prove successful for 100% of
alcohol-dependent individuals, there has been interest in
whether the concomitant use of the two drugs would prove
Table 2 Comparison of the three medications currently approved by the FDA for the treatment of alcohol dependence.
Acamprosate
a Naltrexone
b Disulfiram
c
Mechanism of action Restores balance between Opioid receptor Inhibits alcohol dehydrogenase, a key enzyme
excitatory glutamate and antagonist in alcohol metabolism
inhibitory GABA
neurotransmitter systems
Interactions with alcohol None None Severe adverse reaction includes nausea,
vomiting, flushing, tachycardia
Drug interactions No clinically significant Opiates Phenytoin, oral anticoagulants, isoniazid
interactions
Common side-effects Diarrhea, asthenia, nausea, Elevated liver function Hepatitis, occasional skin eruptions, transient
pruritis, flatulence tests, nausea, headache, mild drowsiness, fatigueability, impotence,
dizziness, nervousness, headache
fatigue, insomnia, vomiting
Serious adverse events  None known Hepatitis Hepatitis, optic neuritis, peripheral neuritis,
polyneuritis and peripheral neuropathy
Contraindications Severe renal impairment Hepatitis or liver failure Hepatitis or liver failure. Current use of
metronidazole, paraldehyde, alcohol, or
alcohol-containing preparations.
a Forest Pharmaceuticals, Inc. 2005
b RiVea (naltrexone hydrochloride) Tablets patient package insert (Mallinckrodt 2005).
c Antabuse (disulfiram) Tablets patient package insert (Odyssey Pharmaceuticals, Inc. 2005).
Abbreviations: GABA, gamma-aminobutyric acid.Neuropsychiatric Disease and Treatment 2006:2(4) 451
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more effective in maintaining abstinence than either drug
alone. A hypothesized theory for this suggests that the two
agents attenuate different aspects of craving. Naltrexone is
an opioid antagonist that indirectly interferes with
dopaminergic neurons in the ventral tegmental area
projecting to the limbic system, and it therefore may relieve
reward craving (Kiefer and Wiedemann 2004). Acamprosate
has been postulated to modify the balance between the
excitatory glutamatergic system and the inhibitory
GABAergic system, thereby diminishing “relief craving”
(Dahchour and De Witte 2000; Boeijinga et al 2004; Scott
et al 2005).
As discussed previously, Kiefer et al (2003) performed
a double-blind, placebo-controlled trial of 160 alcoholics
who were randomized to naltrexone, acamprosate,
naltrexone plus acamprosate, or placebo for 12 weeks. They
found that naltrexone, acamprosate, and the combined
medication were significantly more effective than placebo.
While the naltrexone group showed a tendency for a better
outcome for time to first drink and time to relapse, the
combined medication was most effective, with significantly
lower relapse rates than placebo and acamprosate but not
naltrexone. Kiefer and Wiedemann (2004) evaluated 3 pre-
clinical and 4 clinical studies published on either combined
tolerability or efficacy of acamprosate and naltrexone. None
of these revealed any severe adverse events during combined
treatment. Diarrhea and nausea were the most significant
side-effects. Whereas the preclinical data on efficacy of
combined treatment was inconclusive, clinical data revealed
that combined therapy was superior to both placebo and
acamprosate monotherapy.
The combination of acamprosate and disulfiram has been
evaluated in a small double-blind trial (Besson et al 1998).
The authors found that combination was well tolerated, with
no adverse reactions between acamprosate and disulfiram.
In this small study, the subgroup who received both
medications had a better outcome on cumulative abstinent
days than those on only one or no medication. Additional
investigation in this area is warranted.
Patient-selection characteristics
Previous work supports the theory that pharmacotherapies
may be more successful if pharmacologic agents are matched
to particular characteristics in an alcoholic individual.
Verheul et al (1999) proposed a psychobiological model of
craving for alcohol which included reward craving (desire
for the rewarding or stimulating effects of alcohol), relief
craving (desire for the reduction of tension or arousal), and
obsessive craving (lack of control over intrusive thoughts
about drinking). They proposed that individual differences
Table 3 Studies comparing acamprosate with naltrexone and disulfiram
Study Design Study subjects Main findings
Rubio et al 2001 12-month, randomized, single- 157 recently detoxified alcohol- Time to first relapse was greater in the
blind study comparing dependent men with moderate naltrexone group than acamprosate group
naltrexone and acamprosate dependence and a stable family (p=0.02). At end of study, greater
environment percentage of naltrexone group had not
relapsed compared with acamprosate group
(p=0.009). Cumulative number of days of
abstinence was greater in naltrexone group,
and severity of craving and percentage of
heavy drinking was lower in naltrexone
group than acamprosate group.
Kiefer et al 2003 12-week double-blind, double- 160 recently detoxified alcohol- Acamprosate, naltrexone, and combination
dummy, placebo-controlled dependent patients randomized therapy were superior to placebo. No
trial comparing efficacy of to acamprosate, naltrexone, significant difference in time to first drink
naltrexone, acamprosate, and both, or placebo. and time to relapse between acamprosate
combination of both with and naltrexone. Combined medication
either alone.  resulted in significantly lower relapse rates
than placebo and acamprosate but not
naltrexone.
De Sousa and 1-year open, randomized trial 100 alcohol-dependent males with Relapse occurred later in the disulfiram
De Sousa 2005 comparing efficacy of highly involved family members group than acamprosate group (p=0.0001).
acamprosate and disulfiram who agreed to supervise medication Greater proportion of those in the
(taken for a 8-month period). compliance and attend disulfiram group remained abstinent at the
appointments with patient. end of study than acamprosate group
(p=0.0002).Neuropsychiatric Disease and Treatment 2006:2(4) 452
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would create distinct pathways toward and manifestations
of cravings. Understanding these differences could help
tailor specific pharmacotherapies for specific individual
characteristics and thereby increase pharmacotherapy
efficacy. For example, Johnson et al (2000) demonstrated
that ondansetron, a 5-HT3 antagonist, is a successful
treatment in early-onset, compared with later-onset,
alcoholics. They speculated this was due to the drug
modifying underlying serotenergic dysfunction. In addition,
Monterosso et al (2001) found that individuals with high
levels of alcohol craving or a strong family history of
alcoholism were more likely to benefit from naltrexone
treatment. Gerra et al (1992) found that non-familial
alcoholics significantly reduced drinking with acamprosate,
while familial alcoholics significantly reduced alcohol intake
with fluoxetine, but not with acamprosate. In addition, the
findings of Lesch and Walter (1996) support the matching
of patient characteristics to increase efficacy of acamprosate.
However, in a pooled analysis of 7 randomized controlled
trials comparing acamprosate with placebo, Verheul et al
(2005) did not find statistical differences in potential
predictors of efficacy with acamprosate in alcoholic
individuals.
Acamprosate may be particularly useful in alcohol-
dependent individuals with hepatic impairment or liver
disease. However, to date no pharmacokinetic data are
available in those with severe hepatic impairment.
Naltrexone and disulfiram must be used with caution or
contraindicated in this population because of the risk of
hepatotoxicity. Naltrexone is also contraindicated in those
needing administration of opioid analgesics. On the other
hand, as acamprosate is excreted renally, it is contraindicated
in those with severe renal impairment and must be used
cautiously with decreased doses in those with moderate renal
impairment. Naltrexone and disulfiram may be used in this
patient population.
Conclusions
Acamprosate has been shown to be safe, well tolerated,
and efficacious to help alcohol-dependent individuals
achieve abstinence from alcohol after detoxification. In
combination with psychosocial and behavioral
management programs, it can be an important tool in the
armamentarium of the provider treating this difficult
disease. It has also been shown to be safe and well
tolerated when used in combination with naltrexone, and
may provide even greater benefit in maintaining
abstinence in alcohol-dependent individuals than
monotherapy. Further work is needed to clarify patient
characteristics that may allow individuals to optimally
benefit from one pharmacotherapy versus another. At
present there are conflicting data in the literature on the
optimal time to start acamprosate and further work to
clarify this would be of utmost utility. In addition, this
review demonstrates that the current pharmacotherapies
available for the treatment of alcohol dependence are of
limited clinical utility, particularly in the absence of
psychosocial treatments. The continued search for
effective treatments of this debilitating disease is of
greatest importance.
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